An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions

IF 4.9 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2024-08-03 DOI:10.1080/13543784.2024.2388569

Ezzat A. Ismail, Ahmed I. El-Sakka

引用次数: 0

Abstract

There is a rising concern about developing innovative, efficacious PDE5I molecules that provide better safety, efficacy and tolerability with less adverse effects. Innovative PDE5I with dual target...

查看原文本刊更多论文

用于治疗勃起功能障碍和其他疾病的传统和试验性磷酸二酯酶 5 抑制剂概述

开发安全性更高、疗效更好、耐受性更强、不良反应更少的创新型高效 PDE5I 分子日益受到关注。具有双靶点的创新型 PDE5I...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.